Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics
<p>Abstract</p> <p>Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, specific recurrent chromosomal aberrations can be iden...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-06-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/23 |
| _version_ | 1811277636159143936 |
|---|---|
| author | Gregory Tara K Wald David Chen Yichu Vermaat Johanna M Xiong Yin Tse William |
| author_facet | Gregory Tara K Wald David Chen Yichu Vermaat Johanna M Xiong Yin Tse William |
| author_sort | Gregory Tara K |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist. The largest subgroup of AML patients (~40%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk. The optimal therapeutic strategies for these patients are still largely unclear. Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML (NC-AML). Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPα as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q. Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.</p> |
| first_indexed | 2024-04-13T00:20:26Z |
| format | Article |
| id | doaj.art-a1ff2cbde639484bad1c78de81d047f4 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-13T00:20:26Z |
| publishDate | 2009-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-a1ff2cbde639484bad1c78de81d047f42022-12-22T03:10:49ZengBMCJournal of Hematology & Oncology1756-87222009-06-01212310.1186/1756-8722-2-23Molecular prognostic markers for adult acute myeloid leukemia with normal cytogeneticsGregory Tara KWald DavidChen YichuVermaat Johanna MXiong YinTse William<p>Abstract</p> <p>Acute myeloid leukemia (AML) is a heterogenous disorder that results from a block in the differentiation of hematopoietic progenitor cells along with uncontrolled proliferation. In approximately 60% of cases, specific recurrent chromosomal aberrations can be identified by modern cytogenetic techniques. This cytogenetic information is the single most important tool to classify patients at their initial diagnosis into three prognostic categories: favorable, intermediate, and poor risk. Currently, favorable risk AML patients are usually treated with contemporary chemotherapy while poor risk AML patients receive allogeneic stem cell transplantation if suitable stem cell donors exist. The largest subgroup of AML patients (~40%) have no identifiable cytogenetic abnormalities and are classified as intermediate risk. The optimal therapeutic strategies for these patients are still largely unclear. Recently, it is becoming increasingly evident that it is possible to identify a subgroup of poorer risk patients among those with normal cytogenic AML (NC-AML). Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPα as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q. Further prospective studies are needed to confirm if poorer risk NC-AML patients have improved clinical outcomes after more aggressive therapy.</p>http://www.jhoonline.org/content/2/1/23 |
| spellingShingle | Gregory Tara K Wald David Chen Yichu Vermaat Johanna M Xiong Yin Tse William Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics Journal of Hematology & Oncology |
| title | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| title_full | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| title_fullStr | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| title_full_unstemmed | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| title_short | Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| title_sort | molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics |
| url | http://www.jhoonline.org/content/2/1/23 |
| work_keys_str_mv | AT gregorytarak molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics AT walddavid molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics AT chenyichu molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics AT vermaatjohannam molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics AT xiongyin molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics AT tsewilliam molecularprognosticmarkersforadultacutemyeloidleukemiawithnormalcytogenetics |